BioSpace News Archive

ClostraBio, a biotech company focused on developing novel therapeutic solutions for diseases of the gut, is excited to announce a major breakthrough in targeted metabolite delivery to transform intestinal health.

Median Technologies (ALMDT:PA) (Paris:ALMDT) announced today that Fredrik Brag, CEO and founder of Median Technologies, will provide a company update on February 2nd.

Susan G. Komen®, the world’s leading breast cancer organization, applauds Senator Alice Mann (DFL- Lakeville) and Representative Patty Acomb (DFL- Minnetonka) for working with Komen to introduce legislation that would remove financial barriers to imaging that can rule out breast cancer or confirm the need for a biopsy.

VITRAC Therapeutics, LLC (VITRAC) initiated a Phase 1 Study of VIC-1911 as monotherapy and in combination with sotorasib for the treatment of KRAS G12C-mutant non-small cell lung cancer (NSCLC).

InterAx Biotech AG, a product development company pioneering computational pharmacology for drug discovery, announces the appointment of Dr. Christopher Prior as Chief Executive Officer.

Precigen, Inc. (Nasdaq: PGEN) today announces positive Phase 1 dose escalation and expansion cohort data as of the January 12, 2023 cutoff for the investigational, potential first-in-class PRGN-2012 off-the-shelf (OTS) AdenoVerse™ immunotherapy in patients with recurrent respiratory papillomatosis (RRP).

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, announced the closing of its underwritten public offering of 7,986,111 shares of its common stock.

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced the presentation of additional data from the planned exploratory analysis from the INTRIGUE Phase 3 clinical study of QINLOCK® using circulating tumor DNA (ctDNA) from patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib.

Acasti Pharma Inc. announced Jan D’Alvise, CEO, will present and host one-on-one meetings with investors at the Lytham Partners Investor Select Conference, taking place virtually on January 31, 2023.

The Board of Directors of BD has declared a quarterly dividend of $0.91 per common share, payable on March 31, 2023 to holders of record on March 10, 2023.